Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Rituximab May Slow Beta-Cell Destruction in Patients With Type 1 Diabetes - (DGNews)
    Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial - (BMJ)
    Glucose Intolerance During Pregnancy Associated With Postpartum Cardiovascular Risk - (DGNews)
    TopAbstracts in Diabetes 12/01/2009 - (DGNews)
    Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function - (N Engl J Med)

    News archive

     Recent webcasts/CME - Diabetes
      Clinical Practice In Type 2 Diabetes: After Metformin And Lifestyle, Then What?
      Diabetes and the Heart: Diabetes and Glycemic Control - Endocrine
      Medication Use for Diabetes, Hypertension, and Hypercholesterolemia from 1988-1994 to 2001-2006
      Diabetes and the Heart: Cardiometabolic Screening and Hospital Care
      Diabetes and the Heart: Diabetes and Glycemic Control - Cardiovascular

      Webcasts/CME archive

       Recent cases - Diabetes
        Transient Anti-GAD Antibody Positivity and Acute Pancreatitis with Pancreas Tail Swelling in a Patient with Susceptible Haplotype for Type 1 Diabetes Mellitus
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Troglitazone Improves Cardiovascular Risk Factors Better Than Metformin In Type 2 Diabetes

        A DGReview of :"Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes"
        Diabetes Care

        03/11/2002
        By Mark Greener


        The addition of troglitazone to treatment for type 2 diabetics not responding fully to sulfonylureas appears to improve cardiovascular disease risk factors to a greater extent than does metformin.

        Classic risk factors do not account fully for the increased prevalence of cardiovascular disease among type 2 diabetics. However, a growing body of evidence suggests that insulin resistance and hyperinsulinemia act as cardiovascular disease risk factors in type 2 diabetes.

        Against this background, researchers from the VA San Diego Healthcare System and University of California, San Diego, VA Medical Center, Phoenix, and Quest Diagnostics, California, compared the effect of metformin and troglitazone on cardiovascular disease risk factors in 22 subjects with type 2 diabetes. The patients showed poor glycemic control (HbA1c >8.5 percent) despite taking glyburide 10 mg twice daily. The authors titrated from starting doses of metformin (850 mg) and troglitazone (200 mg), both once daily, until patients attained fasting plasma glucose levels of <120 mg/dl.

        After four months, adding metformin and troglitazone decreased fasting plasma glucose and HbA1c to a similar extent. On the other hand, troglitazone reduced insulin resistance, based on hyperinsulinemic-euglycemic clamp measurements, nearly twice as much as metformin.

        Metformin did not significantly alter blood pressure or low density lipoprotein (LDL) size. Moreover, metformin did not influence levels of LDL cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides or plasminogen activator inhibitor-1. Levels of C-reactive protein, a marker of inflammation, declined by 33 percent in patients taking metformin.

        In contrast, troglitazone increased LDL size, which makes this lipoprotein less atherogenic. Moreover, troglitazone increased levels of HDL cholesterol, while reducing triglyceride concentrations. Furthermore, troglitazone reduced levels of C-reactive protein by 60 percent.

        The authors concluded that in patients with type 2 diabetes who do not fully respond to maximal sulfonylurea doses, adding troglitazone improves cardiovascular disease risk factors to a greater extent than metformin. They added that troglitazone's benefits seem to reflect improved insulin resistance rather than better glycemic control.
        Diabetes Care 2002;25:542-549. "Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send